GlassScriptPhysician profile
Robert Grabowski
NPI 1902827397
$3,259.64
in general payments reported to CMS, 2019-2025
33 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.05 · 2021: $26.98 · 2022: $243 · 2023: $916 · 2024: $1,561 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,792 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,792.38 |
| Education | $163.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $552.42 | 2022-2025 | |
| Novo Nordisk INC | $404.94 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $309.74 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $262.72 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $222.12 | 2024 | Veozah |
| Pfizer INC. | $187.89 | 2022-2025 | |
| Harmony Biosciences LLC | $183.69 | 2023-2025 | Wakix |
| Abbott Laboratories | $163.33 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $140.02 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $101.79 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $58.35 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $57.82 | 2023 | Rexulti, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.20 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $42.14 | 2023-2024 | |
| Sanofi Pasteur INC. | $41.59 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $41.54 | 2022-2024 | Quviviq |
| Dexcom, INC. | $38.58 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $36.84 | 2024-2025 | |
| Dynavax Technologies Corporation | $36.70 | 2022-2023 | Heplisav-B |
| Insulet Corporation | $35.57 | 2024 | Omnipod |
| Amgen INC. | $34.49 | 2023-2024 | Repatha, Otezla |
| Impel Pharmaceuticals INC. | $32.18 | 2022-2023 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $30.89 | 2019-2022 | |
| Tolmar, INC. | $29.60 | 2023 | |
| Ucb, INC. | $23.95 | 2024 | Briviact |
| Alexion Pharmaceuticals, INC. | $23.63 | 2025 | Ultomiris |
| Inspire Medical Systems, INC. | $22.59 | 2023 | Inspire |
| Biogen, INC. | $22.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.80 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $15.94 | 2024 | Camzyos |
| Medtronic, INC. | $14.98 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.42 | 2025 | Gvoke Hypopen |
| Lundbeck LLC | $13.80 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Grabowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.